<DOC>
	<DOCNO>NCT00105352</DOCNO>
	<brief_summary>OBJECTIVE : This study conduct Type 1 Diabetes TrialNet Study Group , fund National Institutes Health , collaboration European C-Peptide Group . The goal evaluate comparability reproducibility measure beta cell function type 1 diabetes compare mixed meal tolerance test ( MMTT ) glucagon stimulation test ( GST ) . These two test compare assess relationship MMTT IV ( intravenous ) Glucagon stimulate C-peptide response measure time peak C-peptide AUC ( area curve ) value . Based understanding type 1 diabetes result immune mediated loss pancreatic beta cell , therapeutic trial newer measure beta cell function evaluate endpoint clinical trial . Direct assessment residual beta cell function appropriate endpoint , retention beta cell function patient T1D know result improved glycemic control reduce hypoglycemia , retinopathy nephropathy . Endogenous beta cell function insulin secretion best measure determination C-peptide ( co-secreted insulin 1:1 molar ratio ) . Intervention study past decade usually use measurement C-peptide . However , relationship measure beta cell function well study . The relative advantage one measure another term variability , sensitivity burden subject unknown . In addition , optimal condition conduct test need determine . An important goal develop international consensus conduct metabolic test context large , multicenter trial involve type 1 diabetes ( T1D ) balance scientific data burden subject .</brief_summary>
	<brief_title>Improving Metabolic Assessments Type 1 Diabetes Mellitus Clinical Trials</brief_title>
	<detailed_description>Overview : The study multi-center , two-arm , randomize clinical trial . Each participant undergo four test within limited period accord test sequence assignment . The test randomly start either MMTT GST . Specific Aims - To compare reliability MMTT Glucagon stimulate C-peptide response measure time peak C-peptide MMTT , peak AUC value test . - To determine relationship MMTT Glucagon stimulate C-peptide response measure time peak C-peptide MMTT peak AUC value test . - To determine impact basal glucose , peak glucose , age participant , time diagnosis , basal C-peptide respect reliability measure relationship MMTT Glucagon result . - Describe palatability , patient compliance , adverse effect test ( MMTT vs. GST ) compare participant investigator burden conduct MMTT Glucagon test . TEST INFORMATION : - Mixed Meal Tolerance Test ( MMTT ) : BOOST liquid meal ( like milkshake ) contain standard amount fat , protein , carbohydrate . BOOST raise blood sugar cause pancreas produce insulin . After drink BOOST , one-half teaspoon blood drawn IV line arm 15 , 30 , 60 , 90 , 120 minute . ( Using IV line avoids multiple needle stick ) . The test take 2 hour . - Glucagon Stimulation Test ( GST ) : Glucagon hormone circulate blood stimulates insulin secretion . Glucagon inject bloodstream IV line , one-half teaspoon blood drawn five time ten minute . The test take 30 minute . OTHER TEST INFORMATION : - Participants test four different day six week period . Participants either ) two MMTTs two GSTs OR b ) two GSTs two MMTTs . Each test do 3-10 day apart . - Participants follow special high carbohydrate diet ( 150 gram ) least three day prior study visit . Dietary information provide . - Participants fast overnight ( least 8 hour ) arrive clinic 7 AM - 10 AM . - It essential participant blood glucose level 70-200 mg/dl morning start test . If blood glucose high low morning test , test re-scheduled another day . - Tests re-scheduled , morning test , blood sugar ketone within acceptable range . Testing could take eight visit test need re-scheduled . - Participants learn whether pancreas still secrete insulin , , much insulin secrete . This information may help diabetes health care team design well insulin regimen diabetes management program improve longterm blood sugar control . - This study help researcher learn test ( MMTT GST ) best use research study look treatment may stop delay type 1 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Informed consent obtain participant ( 12 year age ) parent ( participant 18 year age ) . Assent obtain young child . Age 8 35 year time inclusion Body weight &gt; 30 kg Type 1 diabetes define : ADA ( American Diabetes Association ) criteria judgment physician Duration diabetes : 1 month 3* year ( *The TrialNet Coordinating Center monitor fast Cpeptide level report ensure wide range value include . This review may result widen duration diabetes window allow subject low Cpeptide ) . Must maintain good glycemic control Be willing travel TrialNet Clinical Center minimum four separate visit space 310 day apart , willing complete study within six week period . Actual treatment drug influence beta cell function ( e.g . oral hypoglycaemic agent , beta2receptor agonist ) Actual treatment drug influence insulin sensitivity ( e.g . steroid ) Significant concomitant disease likely interfere glucose metabolism ( e.g . febrile illness within prior 3 day ) Expected poor compliance If female childbearing age , currently pregnant use form birth control Any condition judgement investigator may potentially harmful patient</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Type 1 Diabetes Study Group</keyword>
	<keyword>TrialNet</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>juvenile onset diabetes</keyword>
</DOC>